Last reviewed · How we verify

Sufentanil Infusion

University of Nebraska · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Sufentanil Infusion is a Small molecule drug developed by University of Nebraska. It is currently FDA-approved. Also known as: Sufentanil.

Sufentanil Infusion is a small molecule that acts as a mu opioid receptor agonist, classified as an agonist. It has been studied in various clinical trials for conditions such as normal pregnancy, wound healing, diabetic foot ulcers, kidney transplantation, and chronic kidney disease stage 5D, often in combination with other interventions like clonidine and levobupivacaine.

At a glance

Generic nameSufentanil Infusion
Also known asSufentanil
SponsorUniversity of Nebraska
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sufentanil Infusion

What is Sufentanil Infusion?

Sufentanil Infusion is a Small molecule drug developed by University of Nebraska.

Who makes Sufentanil Infusion?

Sufentanil Infusion is developed and marketed by University of Nebraska (see full University of Nebraska pipeline at /company/university-of-nebraska).

Is Sufentanil Infusion also known as anything else?

Sufentanil Infusion is also known as Sufentanil.

What development phase is Sufentanil Infusion in?

Sufentanil Infusion is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing